Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930648 | 1.00 | NAAA (0.58) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL5180974 | 1.00 | NAAA (0.58) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL3544056 | 0.87 | CRBN (0.60) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL632914 | 0.87 | CRBN (0.60) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL5200673 | 0.87 | CRBN (0.60) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL24907141 | 0.85 | NAAA (0.51) | NAAAGPBAR1ASAH1 | |
| SCHEMBL7423681 | 0.85 | NAAA (0.54) | NAAAALDH1A1GAACTSL | |
| SCHEMBL14812217 | 0.84 | NAAA (0.50) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL14812216 | 0.84 | NAAA (0.50) | NAAAALDH1A1GAACTSLTSHR | |
| SCHEMBL1086370 | 0.83 | ALDH1A1 (0.60) | NAAAALDH1A1GAACTSLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4165023-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1565436-B1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG | 2008-01-10 | — | — | US | disclosed |
| US-7262307-B2 | 1′-benzyl-3-bromo-[1,3′]bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2007-08-28 | — | — | US | disclosed |
| EP-1311518-B1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2005-03-31 | — | — | US | disclosed |
| US-6828442-B2 | Coupling N-benzyl-3-pyrrolidinamine compound with acyl halide; cyclization in presence of a base; reacting with triphenylphosphine to obtain phosphonium salt; reacting with di-tert. -butyl-dicarbonate under hydrogenation conditions | BASILEA PHARMACEUTICA AG (CH) | 2004-12-07 | — | — | US | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-16 | — | — | US | disclosed |
| EP-1311518-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | Basilea Pharmaceutica AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014332-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | NAAA 4581/4885ALDH1A1 2447/4885GAA 4876/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | NAAA 3657/4885ALDH1A1 1965/4885GAA 1006/4885 |
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PNISR, CLK3 | NAAA 1849/4885ALDH1A1 4439/4885GAA 4126/4885 |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PHOSPHO1, PTMS | NAAA 1885/4885ALDH1A1 4354/4885GAA 4099/4885 |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BRD1, BRD4, BET1 | NAAA 3131/4885ALDH1A1 1143/4885GAA 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.